TCE1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage (debt/equity ~0.4%) meaningfully reduces refinancing and interest-rate risk and extends runway for costly clinical programs. This durable financial flexibility supports continued R&D spending and strategic options over the next several months without immediate liquidity stress.
Incentive Plan & Governance SupportShareholder approval to expand the equity incentive pool and re-elect directors signals governance stability and gives management tools to attract and retain scientific and commercial talent. For a clinical-stage biotech, sustained ability to incentivize staff is a durable enabler of pipeline progress and program continuity.
Strong Reported Gross ProfitA strong TTM gross profit suggests favorable product- or partner-level economics versus direct costs. While overall profitability is negative, durable positive gross margins imply that successful commercialization or larger partner deals could translate into sustainable operating leverage and improved margins as scale is achieved.
Bears Say
Declining RevenueA ~45% TTM revenue decline evidences a small, volatile revenue base typical of clinical-stage firms, reducing non-dilutive funding and increasing reliance on milestone deals or equity raises. Structurally, weak top-line trends constrain multi-program funding and heighten execution risk over the medium term.
High Cash BurnSustained operating and free cash outflows near -$222M TTM reflect heavy funding needs to advance clinical programs. Persistently high burn pressures runway, forces recurrent external financing, increases dilution risk, and limits the firm’s ability to expand or accelerate programs without milestone-driven inflows or partnerships.
Deep Negative ProfitabilityExtremely negative net margins (~-346%) and ROE (~-51%) show operating costs far exceed revenues, undermining reinvestment capacity and shareholder value. This structural loss profile means long-term viability depends heavily on successful clinical outcomes rather than current operations, raising binary execution risk.
Celldex News
TCE1 FAQ
What was Celldex Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Celldex Therapeutics’s market cap?
Celldex Therapeutics’s market cap is CHF2.47B.
When is Celldex Therapeutics’s upcoming earnings report date?
Celldex Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Celldex Therapeutics’s earnings last quarter?
Celldex Therapeutics released its earnings results on May 07, 2026. The company reported -$0.954 earnings per share for the quarter, missing the consensus estimate of -$0.93 by -$0.024.
Is Celldex Therapeutics overvalued?
According to Wall Street analysts Celldex Therapeutics’s price is currently Undervalued.
Does Celldex Therapeutics pay dividends?
Celldex Therapeutics does not currently pay dividends.
What is Celldex Therapeutics’s EPS estimate?
Celldex Therapeutics’s EPS estimate is -0.85.
How many shares outstanding does Celldex Therapeutics have?
Currently, no data Available
What happened to Celldex Therapeutics’s price movement after its last earnings report?
Celldex Therapeutics reported an EPS of -$0.954 in its last earnings report, missing expectations of -$0.93. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Celldex Therapeutics?
Currently, no hedge funds are holding shares in CH:TCE1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celldex Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.55%
12-Months-Change
Fundamentals
Return on Equity
-50.72%
Trailing 12-Months
Asset Growth
-30.86%
Trailing 12-Months
Company Description
Celldex Therapeutics
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
TCE1 Stock 12 Month Forecast
Average Price Target
$41.09
Travere Therapeutics
―
Viridian Therapeutics
―
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Options Prices
Currently, No data available
---